MaxCyte, Inc. Agreement with KSQ Therapeutics (5710V)

TIDMMXCT TIDMTTM

RNS Number : 5710V

MaxCyte, Inc.

04 December 2019

MaxCyte, Inc.

("MaxCyte" or the "Company")

MaxCyte and KSQ Therapeutics Announce Development and Commercialization Agreement to Enable the Advancement of KSQ's Adoptive Cell Therapy Programs

Gaithersburg, MD and Cambridge, MA - 04 December 2019: MaxCyte (LSE: MXCT, MXCR), the global cell-based therapies and life sciences company, and KSQ Therapeutics, a biotechnology company using its proprietary CRISPRomics(R) discovery platform to achieve higher probabilities of success in drug development, announced today that the companies have entered into a new development and commercialization agreement. Under the agreement, KSQ gains rights to use MaxCyte's Flow Electroporation(R) technology and ExPERT(TM) instruments for the advancement of KSQ's engineered tumor-infiltrating lymphocyte (eTIL(TM)) programs, which the company is developing for the treatment of PD-1 refractory solid tumors.

Under the terms of the agreement, KSQ obtains non-exclusive clinical and commercial use rights to MaxCyte's cell engineering platform to develop multiple adoptive cell therapies. In return, MaxCyte is eligible to receive certain milestone payments in addition to other licensing fees.

"Adoptive cell therapies hold significant potential to improve outcomes for patients that are otherwise unresponsive to current treatments," said David Meeker, M.D., Chief Executive Officer of KSQ. "MaxCyte's technology will play an important role in enabling the further development of our eTIL(TM) programs as we work to bring best-in-class, cell-based medicines forward for difficult to treat solid tumors."

MaxCyte's ExPERT instrument family represents the next generation of leading, clinically validated, electroporation technology for complex and scalable cellular engineering. By delivering high transfection efficiency with enhanced functionality, the ExPERT platform delivers the high-end performance essential to enable the next wave of biological and cellular therapeutics.

"We are delighted to have signed this agreement with KSQ Therapeutics, a company that's forging an exciting path in the field of adoptive cell therapies with the potential to deliver significant benefits to patients. This is the fifth commercial licence we have signed this year, demonstrating that MaxCyte is the partner of choice for leading technology companies, like KSQ, that are at the cutting edge of cell therapy and gene editing," said Doug Doerfler, President & CEO of MaxCyte, Inc.

About KSQ Therapeutics

KSQ Therapeutics is advancing a pipeline of tumor- and immune-focused drug candidates for the treatment of cancer, across multiple drug modalities including targeted therapies, adoptive cell therapies and immuno-therapies. KSQ's proprietary CRISPRomics(R) discovery engine enables genome-scale, in vivo validated, unbiased drug discovery across broad therapeutic areas. KSQ was founded by thought leaders in the field of functional genomics and pioneers of CRISPR screening technologies, and the company is located in Cambridge, Massachusetts. For more information, please visit the company's website at www.ksqtx.com.

About MaxCyte

MaxCyte is a clinical-stage global cell-based therapies and life sciences company applying its proprietary cell engineering platform to deliver the advances of cell-based medicine to patients with high unmet medical needs. MaxCyte is developing novel CARMA therapies for its own pipeline, with its first drug candidate in a Phase I clinical trial. CARMA is MaxCyte's mRNA-based proprietary therapeutic platform for autologous cell therapy for the treatment of solid cancers. In addition, through its life sciences business, MaxCyte leverages its Flow Electroporation Technology to enable its biopharmaceutical partners to advance the development of innovative medicines, particularly in cell therapy. MaxCyte has placed its flow electroporation instruments worldwide, including with all of the top ten global biopharmaceutical companies. The Company now has more than 80 partnered programme licenses in cell therapy with more than 45 licensed for clinical use. With its robust delivery technology platform, MaxCyte helps its partners to unlock the full potential of their products. For more information, visit www.maxcyte.com.

###

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 (MAR).

For further information, please contact:

 
  MaxCyte Inc. 
    Doug Doerfler, Chief Executive Officer 
    Ron Holtz, Chief Financial Officer                               +1 301 944 1660 
   Nominated Adviser and Joint Corporate 
    Broker 
    Panmure Gordon 
    Emma Earl 
    Freddy Crossley 
    Corporate Broking 
    James Stearns                                                     +44 (0)20 7886 2500 
   Joint Corporate Broker 
    Numis Securities Limited 
    James Black 
    Duncan Monteith                                                  +44 (0)20 7260 1000 
   Financial PR Adviser 
    Consilium Strategic Communications                               +44 (0)203 709 5700 
    Mary-Jane Elliott                                                maxcyte@consilium-comms. 
    Chris Welsh                                                      com 
    Sukaina Virji 
    -------------------------------------------------------------- 
 KSQ Therapeutics 
  Michael Lampe 
  +1 484 575 5040 
  michael@scientpr.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

AGRLFFFFFILVIIA

(END) Dow Jones Newswires

December 04, 2019 02:01 ET (07:01 GMT)

Maxcyte (LSE:MXCT)
Historical Stock Chart
From Oct 2024 to Nov 2024